Insulin has come a long way in the last few decades. Insulin analogues with ultra-rapid and ultra-long half-lives are now commercially accessible. Many new insulin formulations are being developed. Explore the exciting future of diabetes therapy, where cutting-edge innovations such as Twincretins, Triple agonists, Once Weekly Basal insulins, and even the concept of the Bionic pancreas will be unveiled. In this session, you'll gain insights into the evolving landscape of diabetes treatments, including novel therapies and technologies that hold promise for enhanced glycemic control and improved quality of life. Join us for a forward-looking discussion on the potential game-changers in diabetes care that are on the horizon.

Future of Diabetes therapy: Twincretins, Triple agonists, Once Weekly Basal insulins and more

As the field of medicine continues to evolve, the effective utilization of data and digital technologies has become increasingly vital in providing optimal care to patients. In the realm of diabetes management, data-driven approaches offer immense potential for improving patient outcomes, streamlining workflows, and enabling personalized treatment plans. This session aims to equip you with the latest knowledge and insights into harnessing the power of data and digital tools to enhance diabetes management strategies. Join us LIVE as Dr. Sanjeev Phatak talks about the the transformative impact of data and digitization on diabetes management. 

Leveraging Data & Digitization in Diabetes Management

Insulin co-formulation is a combination of basal and bolus insulin analogs. When compared with basal-plus or basal-bolus therapy, insulin degludec/insulin aspart co-formulation has been shown to be a convenient option with similar glycemic control requiring fewer number of injections and with significantly lower risk of nocturnal hypoglycemia and total insulin dose requirement. Let's understand what are the best co-formulations of insulin in Indian scenario. Join us live with an eminent faculty - Dr. Sanjeev Phatak.

Co-formulation Insulin in Indian realities

Association of Physicians of India - APICON 2023 & Medflix jointly present India's largest LIVE medical quiz series! Prepare for the most thrilling quizzes of the year! 7 days, 7 specialties & unlimited learning. With two faculty Quizmasters for this edition, the fun will be doubled. While Dr. Om Lakhani will assess our clinical endocrinology knowledge, Dr. Sanjeev Phatak will test our understanding of diabetes. Join in, play along, and obtain insightful clinical knowledge while winning fun cash prizes and taking home your API certificate of attendance. Experience the joy of learning medicine, tune in on 13th Jan at 9PM! 

APIQUIZ : Endocrinology Edition

The diagnostic criteria for diabetes have been constantly evolving. The International Expert Committee Report recommends a cut-point of ≥6.5% for HbA1c for diagnosing diabetes as an alternative to fasting plasma glucose (FPG ≥7.0 mmol/L). The ADA standard of care has highlighted some important points for diagnosis, like - when to consider testing in overweight and obese patients, and what should be the approach for women diagnosed with GDM. The guidelines also talk about an algorithm for adding and intensifying insulin. Join us live on Medflix to understand all the important highlights from ADA, EASD, and RSSDI.

Key Takeaways From Recently Released International Guidelines : ADA/EASD/RSSDI

Consultant Diabetologist & Metabolic Physician | Vijayratna Diabetes Diagnosis & Treatment Centre, Ahmedabad

Dr. Sanjeev Phatak

4

3.5k

72k

4.6

Sessions Taken

651

4.7

640

4.5

640

4.5

744

4.7

1.1k

4.6

881

4.7